ad image

Company Info

Grifols

Grifols

CDMO

Overview

Grifols Partnership is the contract development and manufacturing platform (CDMO) in Grifols company focused on added value injectable products, with a large international experience in the development and manufacturing of many types of sterile drug products. We are able to leverage the resources and experiences of the larger Grifols organization to provide significant value to our partners.

Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world.

We produce essential plasma medicines for patients to treat chronic, rare and, at times, life-threatening conditions. The company provides a comprehensive portfolio of solutions in transfusion medicine and also offers hospitals, pharmacies and healthcare professionals information and services that deliver efficient, expert medical care.

 

CONTAINERS

Vials (2,5 to 50 mL)

Glass Bottles (50 to 500 mL)

Flexible Containers (PP bags, 50 to 1000 mL)

 

Grifols
Contributions
34 Contributions1 / 2
Leveraging a State-of-the-Art CDMO Facility to Advance Healthcare
New CDMO Facility

Leveraging a State-of-the-Art CDMO Facility to Advance Healthcare

Grifols

PAO-02-23-PATV-04Feb 23, 2023
Innovating to Optimize Quality in Injectable Drugs
Parenteral Drug Products

Innovating to Optimize Quality in Injectable Drugs

Michael Howell

Grifols

PAO-11-022-CL-16Jan 12, 2023
Staying Ahead of Trends in Small-Volume Parenteral Manufacturing
Parenteral Manufacturing

Staying Ahead of Trends in Small-Volume Parenteral Manufacturing

Marga Viñes; Oriol Prat; Oriol Argemi

Grifols

PAO-01-22-R250-08Jan 28, 2022
A CDMO Dedicated to Supporting Small-Volume, Small-Molecule Parenteral Projects
Parenteral Drugs

A CDMO Dedicated to Supporting Small-Volume, Small-Molecule Parenteral Projects

Marga Viñes; Oriol Prat; Oriol Argemi

Grifols

PAO-12-21-CL-02Dec 13, 2021
Grifols
Hyperimmunes

GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology

Grifols

PR-M04-21-018Apr 19, 2021
Grifols
Acquisition

Grifols Reinforces its Innovation Strategy After Completing the Acquisition of GigaGen to Boost a Novel Method to Generate a Wide Range of Immunoglobulins

Grifols

PR-M11-20-045Mar 09, 2021
Trends Shaping the Dynamic Market for Parenterals
Parenterals

Trends Shaping the Dynamic Market for Parenterals

Marga Viñes

Grifols

PAP-Q3-20-CL-018Sep 29, 2020
The Critical Role of Continuous Improvement in Parenteral Drug Manufacturing
Continuous Improvement

The Critical Role of Continuous Improvement in Parenteral Drug Manufacturing

Antonio A. Gomez

Grifols

PAP-Q1-20-CL-010Mar 19, 2020
Customer Engagement and Information Sharing are Essential for Success in Orphan Drug Outsourcing
Orphan Drugs

Customer Engagement and Information Sharing are Essential for Success in Orphan Drug Outsourcing

Marga Viñes

Grifols

PAP-Q3-19-CL-013Oct 29, 2019
Grifols
FDA Approval

Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

Grifols

PR-M07-19-NI-018Jul 09, 2019
Catering to a Growing Demand for Small-Volume Parenteral Manufacturing
Parenteral Manufacturing

Catering to a Growing Demand for Small-Volume Parenteral Manufacturing

Oriol Prat

Grifols

PAO-M04-19-CL-001May 28, 2019
Supporting Small and Emerging Pharma through Collaboration and Specialized Expertise
Parenteral Solutions

Supporting Small and Emerging Pharma through Collaboration and Specialized Expertise

Marga Viñes

Grifols

PAP-Q2-2019-CL-017May 24, 2019
Investing in Form-Fill-Seal Technology
Form-Fill-Seal

Investing in Form-Fill-Seal Technology

Lluc Mercadé

Grifols

PAP-Q1-2019-CL-011Apr 12, 2019
Grifols
Facility Opening

Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR

Grifols

PR-M03-19-NI-082Mar 28, 2019
Grifols
FDA Approval

Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

Grifols

PR-M02-19-NI-017Feb 08, 2019
Continuous Quality is Essential in Parenteral Manufacturing
Quality

Continuous Quality is Essential in Parenteral Manufacturing

Marta Serra

Grifols

PAO-M12-18-CL-003Dec 19, 2018
Grifols
FDA Approval

FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing

Grifols

PR-M10-18-NI-047Oct 15, 2018
Terminal Sterilization for Parenteral Drugs: Finding the Right CDMO Partner
Terminal Sterilization

Terminal Sterilization for Parenteral Drugs: Finding the Right CDMO Partner

Lluis Twose

Grifols

PAP-Q3-18-CL-015Oct 02, 2018
Grifols
FDA Approval

Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins

Grifols

PR-M08-18-NI-123Aug 16, 2018
A Risk Analysis Approach to Producing Environmentally Sensitive Parenterals
Parenterals

A Risk Analysis Approach to Producing Environmentally Sensitive Parenterals

Grifols

PA0-M06-18-CL-007Jun 25, 2018
1 / 2